Multiple new drugs for pain management have been recently introduced or approved, and additional agents are currently under investigation.
Administration of abuse-deterrent formulations of immediate-release oxycodone and extended-release morphine leads to slower and lower absorption rates in nondependent recreational drug users compared with standard oxycodone and morphine formulations.
Egalet announced the launch of Arymo ER extended-release tablets for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
There is a lot of opportunity to improve on what can be offered to patients.
Clinical Pain Advisor Articles
- Brain Plasticity in Patients With Complex Regional Pain Syndrome
- Perturbation-Based Rehabilitation Effective for Chronic Low Back Pain
- IBS-Associated Chronic Pain: Formulation of Core Diagnostic Criteria
- Cannabis Use Associated With Relationship Between Pain and Negative Affect
- Fluoroscopically Guided Sacroiliac Interventions: Appropriate Use Criteria
- Cannabis Use Associated With Aberrant Drug Behaviors
- Walgreens to Carry Naloxone in All Pharmacies to Combat Drug Abuse
- Independent Pharmacies Expanding Services Available to Patients
- Ketamine Exhibits Effective Pain Relief for Refractory Headaches
- Pain In Elite Athletes: IOC Recommendations on Contributing Factors and Treatment Approach
- Naproxen Plus Muscle Relaxants vs Naproxen Monotherapy for Low Back Pain
- Pain Processing: Examining the Role of Oxytocin
- Short- vs Long-Acting Opioids for Osteoarthritis Pain
- Extended-Release Naltrexone Injections Reduce Opioid Dependence
- Depressive Symptoms in Medical Interns Increased With Work-Family Conflicts